Home / Technology & Devices (page 30)

Technology & Devices

Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN), Children’s National Health System and The University of Queensland (UQ) announced today that a study using whole exome sequencing (WES), a method to look at all the genes in the genome at once, yielded clinical diagnoses for 42 percent of patients with white matter abnormalities …

Read More »

Pfizer and WAVE Life Sciences Enter into Drug Development Deal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–WAVE Life Sciences Ltd. (NASDAQ:WVE) today announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined …

Read More »

City of Hope Licensed its AAV-Based Gene Editing Technology to Newly-Formed Genetics Medicines Company

DUARTE, Calif.–(BUSINESS WIRE)–City of Hope today announced that it has licensed its pioneering AAV-based gene editing technology exclusively to Homology Medicines Inc., a newly-formed genetic medicines company. A City of Hope lab led by Saswati Chatterjee, Ph.D., developed the single platform technology that enables both gene editing and gene therapy …

Read More »

FDA Authorizes Quest’s Zika Test for Emergency Use

MADISON, N.J., April 28, 2016 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The test …

Read More »

FDA Approves Collegium’s Abuse-Deterrent Opioid Painkiller Xtampza ER

CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for …

Read More »

Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-Based Design for Metabolic Disease

Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that its scientists have solved the high-resolution X-ray crystal structures of the GLP-1 (glucagon-like peptide 1) and glucagon receptors. Both receptors play important roles in the management of blood glucose levels and are considered to …

Read More »

VolutionRx’s NuQ Biomarker Assay Detects Prostate Cancer Early with Higher Accuracy than PSA Test in Study

NAMUR, Belgium, April 20, 2016 /PRNewswire/ — VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate …

Read More »

AbbVie Enters Cancer Research Deal with University of Chicago

CHICAGO and NORTH CHICAGO, Ill., April 20, 2016 /PRNewswire/ — The University of Chicago and AbbVie (NYSE: ABBV), a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. The joint strategic research agreement …

Read More »

Quest Launches New HCV Test Capabilities for Newly Approved Antiviral Therapies

MADISON, N.J., April 14, 2016 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies, including the …

Read More »

Regeneron and Intellia Partner to Develop CRISPR/Cas Therapeutics

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will …

Read More »